secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001654954-25-003552
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants
--------------------------------------------------------------------------------

- 4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.
- New Series A warrants (5-year term) and Series B warrants (18-month term) issued, each exercisable at $1.284.
- New warrants require shareholder approval per Nasdaq Rule 5635(d); exercise limited to 4.99% (or 9.99%) ownership.
- H.C. Wainwright acted as exclusive financial advisor; fees include 7% cash plus 338,412 HCW warrants at $1.605.
- Company plans to use net proceeds for general corporate purposes including R&D and clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003552/0001654954-25-003552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003552/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-003552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer